Farallon Capital Funds Disclose Over $114M in EXELIXIS Share Sales
Summary
Farallon Capital Management's funds disclosed significant selling activity of EXELIXIS, INC. common stock over the past 60 days, with one key fund reducing its position by nearly 30%. This Schedule 13D/A also updated the beneficial ownership due to internal personnel changes within Farallon.
Key Events
-
Significant Share Sales Disclosed
Farallon Capital Management's funds reported substantial sales of EXELIXIS, INC. common stock over the last 60 days, totaling over $114 million from one key fund alone.
-
Major Fund Reduces Stake
Farallon Healthcare Partners Master, L.P., a key fund within the Farallon group, sold approximately 2.7 million shares, representing nearly 30% of its previous holdings in EXELIXIS, INC.
-
Internal Personnel Changes
The filing updated the list of beneficial owners due to internal management changes at Farallon Capital Management, including one new member and three departures from managing roles.
Analysis
This amended Schedule 13D from Farallon Capital Management, a significant institutional investor, reveals substantial selling activity in EXELIXIS, INC. shares by its affiliated funds over the past two months. The most notable transaction involves Farallon Healthcare Partners Master, L.P., which reduced its position by approximately 2.7 million shares, valued at over $114 million, representing nearly 30% of its previous holdings. While the filing also details administrative changes in Farallon's management, the disclosure of such a large-scale reduction by a major investor could signal a shift in their investment thesis or a rebalancing of their portfolio, which warrants close attention from other investors.
At the time of this filing, EXEL was trading at $42.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.4B. The 52-week trading range was $31.90 to $49.62. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.